Inovio Pharmaceuticals Inc. Common Stock (INO)
Stock · NASDAQ · Health Care
$0.99as of 10/16/2026
Price chart
Active signals
INO Signal Track Record
How signals performed across all stocks →What INO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -9.4% | 35% | August 14, 2026 |
| Bollinger Band Breakdown | 22 | -1.9% | 41% | July 23, 2026 |
| Bollinger Band Breakout | 21 | -11.1% | 19% | July 1, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +8.5% | 60% | September 4, 2026 |
| Any 20-session window (baseline) | -5.1% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates deliver…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 112
- Website
- www.inovio.com/
Fundamentals
- 1-day range
- $0.9606$1.06
- Market cap
- $69.62M
- P/E (trailing)
- —
- P/E (forward)
- -2.36
- EPS (trailing)
- $-1.17
- Dividend yield
- —
- Beta
- 1.68
- Avg. volume
- 4.06M
How Inovio Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Inovio Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- INOInovio Pharmaceuticals Inc. Common Stock$0.99▼ 4.81%Market cap $69.62MP/E —$0.5632$2.72
- XBITXBiotech Inc. Common Stock$2.12▼ 1.85%Market cap $69.51MP/E —$2.09$3.44
- IBIOiBio Inc. Common Stock$0.77▼ 1.28%Market cap $69.05MP/E —$0.7328$3.82
- CTORCitius Oncology Inc. Common Stock$0.768▲ 2.95%Market cap $70.67MP/E —$0.491$2.25
- CLNNClene Inc. Common Stock$3.1▼ 6.34%Market cap $68.24MP/E —$3.24$13.5
- CINGCingulate Inc. Common Stock$4.36▼ 0.68%Market cap $68.02MP/E —$3.16$11.89
- CYPHCypherpunk Technologies Inc. Common Stock$2.57▼ 14.90%Market cap $71.74MP/E —$0.393$4.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INO Inovio Pharmaceuticals Inc. Common Stock | $69.62M | — | $0.99 | ▼ 4.81% | $0.5632$2.72 |
| XBIT XBiotech Inc. Common Stock | $69.51M | — | $2.12 | ▼ 1.85% | $2.09$3.44 |
| IBIO iBio Inc. Common Stock | $69.05M | — | $0.77 | ▼ 1.28% | $0.7328$3.82 |
| CTOR Citius Oncology Inc. Common Stock | $70.67M | — | $0.768 | ▲ 2.95% | $0.491$2.25 |
| CLNN Clene Inc. Common Stock | $68.24M | — | $3.1 | ▼ 6.34% | $3.24$13.5 |
| CING Cingulate Inc. Common Stock | $68.02M | — | $4.36 | ▼ 0.68% | $3.16$11.89 |
| CYPH Cypherpunk Technologies Inc. Common Stock | $71.74M | — | $2.57 | ▼ 14.90% | $0.393$4.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerYahoo · 10/8/2026
- PGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowYahoo · 10/5/2026
- PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Yahoo · 9/30/2026
- Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?Yahoo · 9/24/2026
- Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?Yahoo · 9/14/2026
- Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date LoomsYahoo · 9/11/2026
- Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks TranscriptSeekingAlpha · 9/11/2026
Insider Activity
Insider Actions →- Michael John Sumner · May 20, 2026 · Grant37.7K
- Michael John Sumner · May 20, 2026 · Grant46.9K
- Michael John Sumner · May 20, 2026 · Option Exercise9.4K
- Michael John Sumner · May 20, 2026 · Tax Withholding2.7K @ $1.23
- Jacqueline Elizabeth Shea · May 20, 2026 · Grant100.2K
- Jacqueline Elizabeth Shea · May 20, 2026 · Grant123.8K
- Jacqueline Elizabeth Shea · May 20, 2026 · Option Exercise28.3K
- Jacqueline Elizabeth Shea · May 20, 2026 · Tax Withholding12.3K @ $1.23
- Ann Calby Miller · May 20, 2026 · Grant34.2K
- Ann Calby Miller · May 20, 2026 · Grant41.8K
- Laurent Humeau · May 20, 2026 · Grant27.4K
- Laurent Humeau · May 20, 2026 · Grant34.2K
- Laurent Humeau · May 20, 2026 · Option Exercise6.0K
- Laurent Humeau · May 20, 2026 · Tax Withholding2.2K @ $1.23
- Roger D. Dansey · May 20, 2026 · Grant34.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 31.60M
- Total value held
- $54.48M
- Institutional holders
- 97
- Unknown9.34M
- Unknown3.31M
- Unknown2.90M
- Unknown2.37M
- Unknown2.21M
- Unknown1.47M
- Unknown1.41M
- Unknown1.04M
- Unknown805.0K
- Unknown801.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
INO: PGEN AdenoVerse Pipeline May Drive Growth Beyond Papzimeos
The article examines whether PGEN’s AdenoVerse platform can generate growth that surpasses the company’s current Papzimeos product line. It highlights the potential of the pipeline to broaden Inovio’s therapeutic offerings. The discussion comes as the stock sits near its 16‑touch support level of $1.07 and a neutral RSI of 45.6. Analysts still target the shares at around $3.17 on average.
INO: PGEN AdenoVerse Pipeline May Drive Growth Beyond Papzimeos. The article examines whether PGEN’s AdenoVerse platform can generate growth that surpasses the company’s current Papzimeos product line. It highlights the potential of the pipeline to broaden Inovio’s therapeutic offerings. The discussion comes as the stock sits near its 16‑touch support level of $1.07 and a neutral RSI of 45.6. Analysts still target the shares at around $3.17 on average.